Pharmacokinetics of radiolabeled polyclonal antiferritin in patients with Hodgkin's disease

Clinical Cancer Research

Volumn 5, Issue 10 SUPPL., 1999, Pages

  Lai, Jing ^a,c   Quadri, Syed M ^b   Borchardt, Paul E ^a   Harris, Leigh ^a   Wucher, Robin ^a   Askew, Eileen ^a   Schweichler, Louis ^a   Vriesendorp, Huibert M ^a  

^a Arlington Cancer Center   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c International Isotopes Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIBODY CONJUGATE; FERRITIN ANTIBODY; INDIUM 111; YTTRIUM 90;

ADULT; AFFINITY CHROMATOGRAPHY; BLOOD TOXICITY; CLINICAL ARTICLE; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HODGKIN DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; MALE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; RADIOACTIVITY;

ADULT; ANIMALS; ANTIBODIES; FEMALE; FERRITINS; HODGKIN DISEASE; HUMANS; INDIUM RADIOISOTOPES; MALE; MIDDLE AGED; QUALITY CONTROL; RABBITS; RADIOIMMUNOTHERAPY; TISSUE DISTRIBUTION; YTTRIUM RADIOISOTOPES;

EID: 0032724111     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (21)

1. Eshbar, Z., Order, S. E., and Katz, D. H. Ferritin, a Hodgkin's disease associated antigen. Proc. Natl. Acad. Sci. USA, 71: 3956-3960, 1974.
2. Lenhard, R. E., Order, S. E., Spunberg, J. J., Asbell, S. O., and Leibel, S. A. Isotopic immunoglobulin. A new systemic therapy for advanced Hodgkin's disease. J. Clin. Oncol., 3: 1296-1302, 1985.
3. Vriesendorp, H. M., Herpst, J. M., Leichner, P. K., Klein, J. L., and Order, S. E. Polyclonal yttrium-90 labeled antiferritin for refractory Hodgkin's disease. Int. J. Radiat. Oncol. Biol. Phys., 17: 815-822, 1989.
4. Vriesendorp, H. M., Quadri, S. M., Stinson, R. L., Onyekwere, O. C., Shao, Y., Klein, J. L., Leicnaer, P. K., and Williams, J. R. Selection of reagents for human radioimmunotherapy. Int. J. Radiat. Oncol. Biol. Phys., 22: 37-45, 1992.
5. Vriesendorp, H. M., Herpst, J. M., Germack, M. A., Klein, J. L., Leichner, P. K., Loudenslager, D. M., and Order, S. E. Phase I-II studies of yttrium-90 labeled antiferritin treatment for end-stage Hodgkin's disease, including RTOG 87-01. J. Clin. Oncol., 9: 918-928, 1991.
6. Schneider, S., and McGuire, S. A. Regulatory Analysis on Criteria for the Release of Patients Administered Radioactive Material. Division of Regulatory Applications, Office of Nuclear Regulatory Research, United States Nuclear Regulatory Commission, NUREG-1492 Washington, DC, 1997.
7. Vriesendorp, H. M., Quadri, S. M., Wyllie, C. T., Lai, J., Borchardt, P. E., Harris, L., Wucher, R., Askew, E., and Schweichler, L. Fractionated radiolabeled antiferritin therapy for patients with recurrent Hodgkin's disease. Clin. Cancer Res., 5 (Suppl.): 3324s-3329s, 1999.
8. Quadri, S. M., and Mohammadpour, H. Synthesis of 2-p-aminobenzyl-3-methyl- and 2-p-aminobenzyl-3-benzyl derivatives of diethylene-aminepentaacetic acids (DTPA): carbon backbone modified bifunctional chelating agents. Bioorg. Med. Chern. Lett., 2: 1161-1664, 1992.
9. Schmidt-Nielsen, K. Scaling. Why Is Animal Size So Important? Cambridge, United Kingdom: Cambridge University Press, p. 117.
10. Vriesendorp, H. M., Morton, J. D., and Quadri, S. M. A review of five consecutive studies of radiolabeled immunoglobulin therapy in Hodgkin's Disease. Cancer Res., 55 (Suppl.): 5888s-5892s, 1995.
11. Waldman, T. A., and Strober, W. Metabolism of immunoglobulins. Prog. Allergy, 13: 1-110, 1969.
12. Vriesendorp, H. M., Quadri, S. M., Andersson, B. S., and Dicke, K. A. Hematological side effects of radiolabeled immunoglobulin therapy. Exp. Hematol., 24: 1183-1190, 1996.
13. Wang, S., Quadri, S. M., Tang, X. Z., Stephens, L. C., Lollo, C. P., Bartholomew, R. M., and Vriesendorp, H. M. Liver toxicity induced by combined external beam irradiation and radioimmunoglobulin therapy. Radiat. Res., 141: 294-302, 1995.
14. 2 fragments of monoclonal antiferritin in nude mouse model. J. Nucl. Med., 34: 2251-2258, 1993.
15. Jandl, J. H. Blood Textbook of Hematology, Ed. 2, pp. 1099-1102. Boston, MA: Little, Brown & Co., 1996.
16. Abbas, A. K., Lichtman, A. H., and Pober, J. S. Cellular and Molecular Immunology, pp. 358-360. Philadelphia: W. B. Saunders Co., 1991.
17. Eisen, H. N. Immunology, Ed. 2. Hagerstown, MD: Harper & Row, 1980.
18. Junghans, R. P., and Anderson, C. L. The protection receptor for IgG catabolism is the β2 microglobulin-containing intestinal transport receptor. Proc. Natl. Acad. Sci. USA, 93: 5512-5517, 1996.
19. Brambell, F. W. R., Hemmings, W. A., and Morris, I. G. A theoretical model of γ-globulin catabolism. Nature (Lond.), 203: 1352-1355, 1964.
20. Bibby, M. C., Double, J. A., Loadman, P. M., and Duke, C. V. Reduction of tumor blood flow by flavone acetic acid: a possible component to therapy. J. Natl. Cancer Inst., 81: 216-220, 1989.
21. Chaplin, D. J., Hill, S. A., Bell, K. M., and Tozer, G. M. Modification of tumor blood flow: current status and future directions. Semin. Radiat. Oncol., 8: 143-150, 1998.